Research map: A mouse PDX clinical trial reveals broad efficacy of niraparib and vc-seco-DUBA anti-HER2 ADC SYD985 in HER2/neu expressing endometrial cancer

Back to the article

Papers in this map

  1. Integrated genomic characterization of endometrial carcinoma · Douglas A. Levine · 2013 · 5971 citations · Cited by this paper
  2. 2-deoxy-d-ribose: A multifaceted player at the crossroads of cancer metabolism · 2026 · Related
  3. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma · Nicole Concin · 2020 · 2015 citations · Cited by this paper
  4. Activity-dependent metabolic vulnerability in the APPPS1 Alzheimer’s disease mouse model during isoflurane anesthesia · 2026 · Related
  5. Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research · Manuel M. Hidalgo · 2014 · 1815 citations · Cited by this paper
  6. Tailoring pH-responsive charge-conversional interfaces in ionizable lipid-based nanoliposomes for synchronized co-delivery and synergistic therapy of triple-negative breast cancer · 2026 · Related
  7. Endometrial cancer · Emma J Crosbie · 2022 · 1383 citations · Cited by this paper
  8. Preserved motor function and prolonged sensory local anesthesia with novel PLGA microparticles co-encapsulating lidocaine and capsaicin · 2026 · Related
  9. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial · Funda Meric‐Bernstam · 2023 · 1061 citations · Cited by this paper
  10. Iron–quercetin complex induces ex vivo proteomic remodeling in circulating proangiogenic cells derived from human peripheral blood mononuclear cells · 2026 · Related
  11. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes · Yoko S. DeRose · 2011 · 1034 citations · Cited by this paper
  12. Acetonic extract of Saskatoon berry attenuates amyloid-associated neurotoxicity in cellular and Drosophila melanogaster Alzheimer’s disease models · 2026 · Related
  13. A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer · Andrea Bertotti · 2011 · 964 citations · Cited by this paper
  14. Design of sunflower trypsin inhibitor 1 derived probes targeting the LDLR and evaluation of their brain delivery · 2026 · Related
  15. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study · Udai Banerji · 2019 · 577 citations · Cited by this paper
  16. The chalcone derivative DN-053 attenuates renal fibrosis and inhibits p38 MAPK and STAT3 signaling in renal fibroblasts · 2026 · Related
  17. Patient-derived xenograft models in cancer therapy: technologies and applications · Yihan Liu · 2023 · 493 citations · Cited by this paper
  18. Urinary biomarkers in muscle-invasive bladder cancer: Current state and open opportunities for neoadjuvant chemotherapy response prediction and patient stratification · 2026 · Related
  19. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial · Shannon Neville Westin · 2023 · 374 citations · Cited by this paper
  20. HER2-positive gastric cancer · Narikazu Boku · 2013 · 364 citations · Cited by this paper
  21. ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025 · Nicole Concin · 2025 · 302 citations · Cited by this paper
  22. Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals · Ruili Wang · 2025 · 279 citations · Cited by this paper
  23. Trastuzumab in the Treatment of Breast Cancer · Sofia Maximiano · 2016 · 235 citations · Cited by this paper
  24. The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers · Miranda M.C. van der Lee · 2015 · 217 citations · Cited by this paper
  25. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: A gynecologic oncology group study · T. A. Grushko · 2007 · 182 citations · Cited by this paper
  26. Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform · Wim H.A. Dokter · 2014 · 168 citations · Cited by this paper
  27. Molecular correlates of platinum response in human high‐grade serous ovarian cancer patient‐derived xenografts · Monique D. Topp · 2014 · 143 citations · Cited by this paper
  28. Mouse hospital and co-clinical trial project—from bench to bedside · John G. Clohessy · 2015 · 130 citations · Cited by this paper
  29. The Chemistry Behind ADCs · Vesela Kostova · 2021 · 129 citations · Cited by this paper
  30. Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers · Sandra Misale · 2015 · 128 citations · Cited by this paper
  31. p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification · Amy Jamieson · 2021 · 118 citations · Cited by this paper
  32. Activation of Wnt signaling promotes olaparib resistant ovarian cancer · Tomomi M. Yamamoto · 2019 · 103 citations · Cited by this paper
  33. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy · Douglas A. Rottmann · 2019 · 90 citations · Cited by this paper
  34. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study · Britt Kristina Erickson · 2020 · 89 citations · Cited by this paper
  35. The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer · Elisabeth Diver · 2015 · 85 citations · Cited by this paper
  36. Evaluating Patient-Derived Colorectal Cancer Xenografts as Preclinical Models by Comparison with Patient Clinical Data · Manoel Nunes · 2015 · 73 citations · Cited by this paper
  37. Duocarmycin-based antibody–drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress · Hangping Yao · 2021 · 70 citations · Cited by this paper
  38. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors · Kurt W. Evans · 2017 · 65 citations · Cited by this paper
  39. Linker Design for the Antibody Drug Conjugates: A Comprehensive Review · Yaxin Lei · 2025 · 65 citations · Cited by this paper

Source: OpenAlex (CC0)